Catalyst Pharmaceuticals Inc (CPRX)
Debt-to-equity ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 727,632 | 660,941 | 608,655 | 561,412 | 387,881 | 348,548 | 375,294 | 333,661 | 300,421 | 270,041 | 241,092 | 220,221 | 206,831 | 198,661 | 188,944 | 178,651 | 169,598 | 156,628 | 111,201 | 99,676 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $727,632K
= 0.00
The debt-to-equity ratio of Catalyst Pharmaceuticals Inc has consistently been at 0.00 for the period spanning from March 31, 2020, to December 31, 2024. This indicates that the company has been operating without any long-term debt obligations, relying entirely on equity financing to support its operations and investments. A debt-to-equity ratio of 0.00 typically suggests a conservative financial structure with a low level of financial leverage. This implies that the company may have lower financial risk compared to companies with higher debt levels. However, it is important to note that a very low debt-to-equity ratio could also mean missed opportunities for leveraging debt to potentially enhance returns for shareholders.
Peer comparison
Dec 31, 2024